Impact of PD-L1 Status on the Development of Cutaneous Immune-Related Adverse Events in Non-Small-Cell Lung Cancer Patients Receiving Immunotherapy.

Life (Basel) · 2026 · PMC13117193 · PMID 42073445

Europe PMC DOI

hedged sentence

0.0750

closest p · 1.5× alpha

0.0750

boldest claim

The sentences

did not reach statistical significancep = 0.075so close (0.05 < p ≤ 0.1)

Similarly, pruritus was reported in 9.8% (8 patients) of the ipilimumab plus nivolumab group compared to 18.7% (38 patients) in the pembrolizumab group, which also did not reach statistical significance ( p = 0.075), ( Table 4 , used Pearson chi-square test).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.